NCT00247676View on ClinicalTrials.gov

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 28, 2009

Conditions
Liver NeoplasmsUnresectable Hepatocellular Carcinoma
Interventions
DRUG

Sunitinib (SU011248)

Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.

Trial Locations (8)

110

Pfizer Investigational Site, Taipei

44805

Pfizer Investigational Site, Saint Herrblain Cedex

92118

Pfizer Investigational Site, Clichy

4422935062

Pfizer Investigational Site, Rennes

110-744

Pfizer Investigational Site, Seoul

135-710

Pfizer Investigational Site, Seoul

138-736

Pfizer Investigational Site, Seoul

152-703

Pfizer Investigational Site, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00247676 - An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer | Biotech Hunter | Biotech Hunter